Novavax Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>Novavax Inc. filed its Q1 2024 10-Q report detailing financial performance and balance sheet information.</b>

AI Summary

NOVAVAX INC (NVAX) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Novavax Inc. reported financial results for the first quarter of 2024. The company's filing covers the period from January 1, 2024, to March 31, 2024. Key financial data points and balance sheet information as of March 31, 2024, and December 31, 2023, are included. The filing details various equity and retained earnings accounts. It also references specific product segments and royalty payments.

Why It Matters

For investors and stakeholders tracking NOVAVAX INC, this filing contains several important signals. This 10-Q provides investors with the latest quarterly financial snapshot of Novavax, crucial for understanding its current financial health and operational performance. The detailed breakdown of financial accounts and segments offers insights into revenue streams and equity structure, aiding in investment analysis.

Risk Assessment

Risk Level: medium — NOVAVAX INC shows moderate risk based on this filing. The company's financial performance is subject to the inherent risks of the biotechnology sector, including product development, regulatory approvals, and market competition, as indicated by the detailed financial reporting in the 10-Q.

Analyst Insight

Monitor Novavax's upcoming earnings reports and investor calls for updates on product pipeline progress and commercialization strategies following this 10-Q filing.

Revenue Breakdown

Key Numbers

• 2024-03-31 — Reporting Period End Date (Conformed period of report)
• 2024-05-10 — Filing Date (Filed as of date)
• 2024-01-01 — Quarterly Period Start Date (Reporting period)
• 2024-03-31 — Quarterly Period End Date (Reporting period)

Key Players & Entities

• NOVAVAX INC (company) — Filer
• 2024-03-31 (date) — Conformed period of report
• 2024-05-10 (date) — Filed as of date
• 2024-01-01 (date) — Reporting period start date
• 2024-03-31 (date) — Reporting period end date
• Sanofi Pasteur Inc. (company) — Member in financial reporting

FAQ

Industry Context

Novavax operates in the biotechnology sector, focusing on vaccine development and commercialization. This sector is characterized by significant research and development costs, lengthy regulatory approval processes, and intense competition.

Regulatory Implications

Companies in the biotechnology sector are subject to stringent regulations from health authorities like the FDA regarding product safety, efficacy, and manufacturing standards. Compliance is critical for market access and revenue generation.

What Investors Should Do

1. Review the detailed financial statements in the 10-Q to assess revenue trends and cost structures.
2. Analyze the balance sheet for changes in assets, liabilities, and equity compared to the previous quarter.
3. Monitor future filings for updates on product development milestones and regulatory submissions.

Year-Over-Year Comparison

This filing represents the first quarterly report for 2024, providing an update on the company's financial position and performance since the end of the fiscal year 2023.

Key Financial Figures

• $0.01 — ich registered Common Stock, Par Value $0.01 per share NVAX The Nasdaq Global Select

Filing Documents

• nvax-20240331.htm (10-Q) — 909KB
• nvax-20240331xexhibit101.htm (EX-10.1) — 53KB
• nvax-20240331xexhibit102.htm (EX-10.2) — 348KB
• nvax-20240331xexhibit103.htm (EX-10.3) — 357KB
• nvax-20240331xexhibit104.htm (EX-10.4) — 372KB
• nvax-20240331xex311.htm (EX-31.1) — 10KB
• nvax-20240331xex312.htm (EX-31.2) — 11KB
• nvax-20240331xex321.htm (EX-32.1) — 5KB
• nvax-20240331xex322.htm (EX-32.2) — 5KB
• image_01a.jpg (GRAPHIC) — 6KB
• image_02.jpg (GRAPHIC) — 163KB
• image_0a.jpg (GRAPHIC) — 125KB
• image_0b.jpg (GRAPHIC) — 0KB
• image_1.jpg (GRAPHIC) — 684KB
• image_11a.jpg (GRAPHIC) — 684KB
• image_12.jpg (GRAPHIC) — 684KB
• nvax-20240331_g1.jpg (GRAPHIC) — 198KB
• 0001000694-24-000031.txt (&nbsp;) — 10844KB
• nvax-20240331.xsd (EX-101.SCH) — 43KB
• nvax-20240331_cal.xml (EX-101.CAL) — 49KB
• nvax-20240331_def.xml (EX-101.DEF) — 268KB
• nvax-20240331_lab.xml (EX-101.LAB) — 579KB
• nvax-20240331_pre.xml (EX-101.PRE) — 446KB
• nvax-20240331_htm.xml (XML) — 674KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 1 Item 1. Consolidated Financial Statements 1 Unaudited Consolidated Statements of Operations and Unaudited Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2024 and 2023 2 Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023 3 Unaudited Consolidated Statements of Changes in Stockholders' Deficit for the three months ended March 31, 2024 and 2023 4 Unaudited Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023 4 Notes to the Consolidated Financial Statements (unaudited) 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 38

OTHER INFORMATION

PART II. OTHER INFORMATION 38 Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 41 Item 5 Other Information 43 Item 6. Exhibits 44

SIGNATURES

SIGNATURES 45 i Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 1 Table of Contents NOVAVAX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share information) (unaudited) For the Three Months Ended March 31, 2024 2023 Revenue: Product sales $ 82,324 $ ( 7,457 ) Grants — 87,379 Royalties and other 11,531 1,029 Total revenue 93,855 80,951 Expenses: Cost of sales 59,209 34,086 Research and development 92,679 247,101 Selling, general, and administrative 86,798 112,532 Total expenses 238,686 393,719 Loss from operations ( 144,831 ) ( 312,768 ) Other income (expense): Interest expense ( 4,111 ) ( 4,316 ) Other income 3,654 24,362 Loss before income taxes ( 145,288 ) ( 292,722 ) Income tax expense 2,262 1,183 Net loss $ ( 147,550 ) $ ( 293,905 ) Net loss per share: Basic and diluted $ ( 1.05 ) $ ( 3.41 ) Weighted average number of common shares outstanding: Basic and diluted 139,916 86,158 CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (in thousands) (unaudited) For the Three Months Ended March 31, 2024 2023 Net loss $ ( 147,550 ) $ ( 293,905 ) Other comprehensive loss: Foreign currency translation adjustment ( 13,547 ) 3,211 Other comprehensive income (loss) ( 13,547 ) 3,211 Comprehensive loss $ ( 161,097 ) $ ( 290,694 ) The accompanying notes are an integral part of these financial statements. 2 Table of Contents NOVAVAX, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share information) March 31, 2024 December 31, 2023 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 480,586 $ 568,505 Restricted cash 10,455 10,424 Accounts receivable 21,380 297,240 Inventory 15,778 41,696 Prepaid expenses and other current assets 198,921 226,023 Total current assets 727,120 1,143,888 Property and equipment, net 291,093 305,771 Right of use asset, net 181,175 185,218 Goodwill 123,179 127,454 Other non-current assets 30,967 35,159 Total assets $ 1,353,534 $ 1,797,490 LIABILITIES A

View Full Filing

View this 10-Q filing on SEC EDGAR